Prab: CSV import

2025-02-15T11:17:36Z

CSV import

← Older revision		Revision as of 11:17, 15 February 2025
Line 1:		Line 1:
	~~'''~~Sofituzumab vedotin''' is an [[antibody-drug conjugate]] designed for the treatment of [[cancer]]. It is composed of a [[monoclonal antibody]], sofituzumab, linked to a [[cytotoxic]] agent, vedotin. The antibody targets the [[protein]] nectin-4, which is overexpressed in several types of cancer, including [[bladder cancer]], [[breast cancer]], and [[lung cancer]]. The cytotoxic agent is then released into the cancer cell, causing cell death.		{{DISPLAYTITLE:Sofituzumab vedotin}}

	== ~~Mechanism of action~~ ==		== Overview ==
	Sofituzumab vedotin ~~works by targeting~~ the ~~protein nectin-4, which is overexpressed in several~~ types of cancer. ~~The~~ monoclonal antibody~~, sofituzumab, binds~~ to ~~nectin-4 on the surface of cancer cells. The~~ cytotoxic agent, ~~vedotin~~, ~~is then released into~~ the cancer ~~cell~~, ~~causing cell death~~.		'''Sofituzumab vedotin''' is an [[antibody-drug conjugate]] (ADC) designed for the treatment of certain types of [[cancer]]. It combines a monoclonal [[antibody]] specific to a target antigen with a potent cytotoxic agent, [[monomethyl auristatin E]] (MMAE), through a stable linker. This allows for targeted delivery of the cytotoxic drug to cancer cells, minimizing damage to normal tissues.

	== ~~Clinical trials~~ ==		== Mechanism of Action ==
	Sofituzumab vedotin ~~has been tested in several~~ [[~~clinical trials~~]] ~~for various types~~ of cancer. ~~In a phase I trial for patients with metastatic urothelial cancer~~, the ~~drug showed promising results, with a response rate~~ of ~~44%~~. ~~A phase II trial for patients with metastatic breast cancer~~ is ~~currently ongoing~~.		Sofituzumab vedotin works by targeting a specific [[antigen]] expressed on the surface of cancer cells. The monoclonal antibody component of the ADC binds to this antigen, facilitating the internalization of the entire conjugate into the cell. Once inside, the linker is cleaved, releasing MMAE, which disrupts the [[microtubule]] network, leading to cell cycle arrest and apoptosis.

	== ~~Side effects~~ ==		== Development and Clinical Trials ==
	~~Common side effects~~ of sofituzumab vedotin ~~include fatigue~~, ~~nausea~~, and ~~decreased appetite~~. ~~Serious side effects can include peripheral neuropathy~~, ~~neutropenia~~, and ~~skin reactions~~.		The development of sofituzumab vedotin involves extensive [[preclinical]] and [[clinical trials]] to evaluate its safety, efficacy, and optimal dosing. These trials are conducted in phases, starting with [[Phase I]] to assess safety and dosage, followed by [[Phase II]] and [[Phase III]] to evaluate efficacy and side effects in larger patient populations.

	== ~~See also~~ ==		== Side Effects ==
			As with other ADCs, sofituzumab vedotin can cause a range of side effects. Common adverse effects include [[peripheral neuropathy]], [[fatigue]], and [[hematologic toxicity]]. Management of these side effects is crucial to ensure patient compliance and treatment efficacy.

			== Future Directions ==
			Research is ongoing to improve the efficacy and safety of sofituzumab vedotin. This includes exploring combination therapies with other [[chemotherapeutic agents]] or [[immunotherapies]], as well as identifying biomarkers for patient selection.

			== Related Pages ==
	* [[Antibody-drug conjugate]]		* [[Antibody-drug conjugate]]
	* [[Monoclonal antibody]]		* [[Monoclonal antibody]]
	* [[~~Cytotoxicity~~]]		* [[Cancer treatment]]
	* [[~~Nectin-4~~]]		* [[Chemotherapy]]
	* [[~~Clinical trial~~]]
			== Gallery ==
			[[File:Vedotin_ADCs.svg\|thumb\|right\|Diagram of an antibody-drug conjugate using vedotin.]]

	[[Category:Antibody-drug conjugates]]		[[Category:Antibody-drug conjugates]]
	[[Category:Cancer treatments]]		[[Category:Cancer treatments]]
	~~[[Category:Monoclonal antibodies]]~~
	~~[[Category:Cytotoxic drugs]]~~

	~~{{stub}}~~

Prab: CSV import

2024-02-25T14:33:14Z

CSV import

New page

'''Sofituzumab vedotin''' is an [[antibody-drug conjugate]] designed for the treatment of [[cancer]]. It is composed of a [[monoclonal antibody]], sofituzumab, linked to a [[cytotoxic]] agent, vedotin. The antibody targets the [[protein]] nectin-4, which is overexpressed in several types of cancer, including [[bladder cancer]], [[breast cancer]], and [[lung cancer]]. The cytotoxic agent is then released into the cancer cell, causing cell death.

== Mechanism of action ==
Sofituzumab vedotin works by targeting the protein nectin-4, which is overexpressed in several types of cancer. The monoclonal antibody, sofituzumab, binds to nectin-4 on the surface of cancer cells. The cytotoxic agent, vedotin, is then released into the cancer cell, causing cell death.

== Clinical trials ==
Sofituzumab vedotin has been tested in several [[clinical trials]] for various types of cancer. In a phase I trial for patients with metastatic urothelial cancer, the drug showed promising results, with a response rate of 44%. A phase II trial for patients with metastatic breast cancer is currently ongoing.

== Side effects ==
Common side effects of sofituzumab vedotin include fatigue, nausea, and decreased appetite. Serious side effects can include peripheral neuropathy, neutropenia, and skin reactions.

== See also ==
* [[Antibody-drug conjugate]]
* [[Monoclonal antibody]]
* [[Cytotoxicity]]
* [[Nectin-4]]
* [[Clinical trial]]

[[Category:Antibody-drug conjugates]]
[[Category:Cancer treatments]]
[[Category:Monoclonal antibodies]]
[[Category:Cytotoxic drugs]]

{{stub}}

Sofituzumab vedotin - Revision history

Prab: CSV import

Prab: CSV import